China Flu Diagnostic and Treatment Market - Strategic Insights and Forecasts (2026-2031)

The China Flu Diagnostic and Treatment market is forecast to grow at a CAGR of 22.0%, reaching USD 23.8 billion in 2031 from USD 8.8 billion in 2026.

The Chinese flu diagnostic and treatment market is currently undergoing a regulatory maturation phase as the National Medical Products Administration (NMPA) implements stricter Quality Management System (QMS) legislation effective November 1, 2026. Healthcare providers are responding to this shift by upgrading laboratory infrastructure to meet revised Good Manufacturing Practice (GMP) requirements for medical devices. This transition is becoming critical as China CDC's virologic surveillance continues to identify high-severity seasons, such as the 2024–2025 period which saw 51 million illnesses. Structural demand is increasing for analyzer-based digital readers that provide consistent results compared to human review. Consequently, the industry is reaching an outcome where foreign and domestic manufacturers must demonstrate rigorous verification and validation (V&V) to maintain market access.

Market Dynamics

Drivers

• Rising Epidemic Frequency: Increased seasonal and pandemic surveillance is currently propelling the adoption of molecular diagnostic methods across China.

• Point-of-Care Expansion: Decentralized clinical use is growing as healthcare facilities are currently enlisting automated, data-linked testing kits to reduce diagnostic errors.

• Multiplex Integration: The introduction of tests detecting influenza alongside other respiratory pathogens is currently increasing clinical utility for outpatient clinics.

• Technological Convergence: AI and machine learning are currently supporting the automation of test interpretation to enhance sensitivity relative to traditional optical methods.

Restraints and Opportunities

• Pricing Reform Pressure: Centralized procurement and healthcare pricing reforms in China are continuing to challenge the profit margins of global diagnostic leaders.

• Stricter Compliance Hurdles: The elevation of QMS requirements is currently forcing foreign manufacturers to submit home-country approval and extensive evidence of quality assurance.

• Home-Testing Kits (Opportunity): Growing preference for decentralized healthcare is providing a significant opening for the expansion of influenza home-diagnostic kits.

• Pathology and Molecular Solutions (Opportunity): Strong demand in these segments is currently providing a pathway for companies to offset losses in traditional diagnostic sectors.

Supply Chain Analysis

The supply chain for flu diagnostics in China is currently shifting toward a model of localized quality control as NMPA's Announcement No. 107 of 2025 elevates management responsibility for all manufacturers. MAHs are increasing their oversight of contract manufacturing organizations (CMOs) to comply with new "marketing release" mandates. This evolution is becoming critical as the demand for rapid molecular assays is currently outpacing the supply of traditional optical lateral flow tests.

Government Regulations

Key Developments

• Abbott-Exact Sciences Merger (March 2026): Abbott is currently integrating Exact Sciences' portfolio to bolster its global diagnostic footprint.

• NMPA QMS Final Implementation (November 2025): Regulators confirmed that new legislation for medical device quality management will be mandatory starting November 2026.

• Roche Next-Gen Sequencing Launch (October 2025): Roche successfully launched a technology capable of decoding an entire human genome in less than four hours to set new standards in molecular diagnostics.

Market Segmentation

By Offering

Rapid molecular assays are currently gaining market share over conventional RIDTs as they offer superior sensitivity and are essential for timely public health responses. Diagnostics are witnessing a shift toward semi-quantitative and digital-read formats. This transition is resulting in a market where therapeutics are becoming more targeted based on rapid, strain-specific identification.

By End-User

Hospital laboratories remain the primary segment for molecular diagnostics, as they are currently upgrading equipment to comply with NMPA's separate "Quality Assurance" chapters. Outpatient clinics are currently adopting digital RIDTs due to their ease of use and lack of specialized training requirements during busy flu seasons. Consequently, reference laboratories are reaching a structural outcome where they handle complex pandemic surveillance and high-volume seasonal testing.

By Age Group

The 65 years segment is currently accounting for 57% of flu-related hospitalizations and 71% of deaths, driving a critical need for accurate diagnostic monitoring in this group. Children (0-14 years) are witnessing high demand for rapid testing as school-based outbreaks are currently a major driver for pediatric medical visits. This movement is forcing a realignment of the market toward age-specific diagnostic interventions and vaccination effectiveness assessments.

List of Companies

• Abbott

• Roche Diagnostics China

• BD (Becton, Dickinson and Company)

• Thermo Fisher Scientific

• 3M

• Quidel Corporation

• F. Hoffmann-La Roche Ltd

• Hologic, Inc.

• Meridian Bioscience, Inc.

• SEKISUI Diagnostics, LLC

Company Profiles

• Roche Diagnostics China: Strategically distinct for its focus on pathology and molecular solutions, the company is successfully offsetting China's pricing reforms through high-efficiency gains and 7% group sales growth in 2025.

• Abbott: Notable for its robust innovation pipeline, the company is currently expanding its diagnostic leadership to over USD 12 billion through strategic global acquisitions and product launches.

• Quidel Corporation: Distinguished by its strength in point-of-care testing, the company is currently leveraging the shift toward digital RIDTs and analyzer-based readers for consistent clinical results.

Analyst View

The Chinese flu diagnostic market is entering a "Regulatory Conformity" phase. Success for participants now depends on navigating NMPA's strict 2026 GMP requirements while successfully integrating molecular precision into the burgeoning outpatient and point-of-care segments through 2031.

China Flu Diagnostic and Treatment Market Scope: